BOONTON, N.J., Sept. 19, 2017 /PRNewswire/ -- Enteris BioPharma, Inc., a biotechnology company developing innovative drug products built around its proprietary delivery technologies, today announced that Joel Tune, Chief Executive Officer and Executive Chairman of Enteris BioPharma, will present at the 10th Annual International Partnering Conference BioPharm America, being held September 26-27, 2017, at the Boston Sheraton Hotel, Boston, MA.
Mr. Tune will present Enteris' corporate growth strategy and its focus on developing orally delivered peptide therapeutics for a broad range of treatment indications. Since its founding in 2013, Enteris has advanced multiple internal and external programs leveraging its Peptelligence™ platform, a novel formulation technology that enables oral delivery of molecules that are typically injected, including peptides and BCS class II, III and IV small molecules. Most recently, Enteris announced that the first woman has been dosed in its Phase 2a clinical trial to evaluate Ovarest™, an oral formulation of leuprolide, for the treatment of endometriosis. Ovarest™ was developed utilizing Enteris' Peptelligence platform.
|
Event: |
BioPharm America |
|
Date: |
Tuesday, September 26, 2017 |
|
Time: |
2:30p.m. (Eastern Time) |
|
Location: |
Sheraton Boston Hotel |
About Enteris BioPharma
Enteris BioPharma, Inc. is a privately held, New Jersey-based biotechnology company offering innovative formulation solutions built around its proprietary drug delivery technologies. The Company's proprietary oral delivery technology – Peptelligence™ – has been the subject of numerous feasibility studies and active development programs, several of which are in late stage clinical development. Additionally, Enteris BioPharma is advancing an internal product pipeline of oral tablet reformulations of drug products that address significant treatment opportunities for which there is no oral delivery option. Enteris BioPharma's most advanced internal product candidate, Ovarest™ (oral leuprolide tablet), is an oral peptide being developed for the treatment of endometriosis. For more information on Enteris BioPharma and its proprietary oral delivery technology, please visit http://www.EnterisBioPharma.com.
Enteris Media Relations:
Jason Rando / Dave Schemelia
Tiberend Strategic Advisors, Inc.
+1.212.827.0020
jrando@tiberend.com
dschemelia@tiberend.com
SOURCE Enteris BioPharma, Inc.